Transcriptomics

Dataset Information

0

MEK inhibition rewires enhancer landscapes in RAS-driven Rhabdomyosarcoma to unlock a myogenic differentation block


ABSTRACT: Trametinib-treated rhabdomyosarcoma cells undergo transcriptional reprogramming akin to myogenic differentiation. This reprogramming is induced by loss of ERK-mediated inhibition of MYOG expression. Restoration of MYOG allows establishment of super-enhancers at genes expressed by terminally differentiated myotubes. Our findings demonstrate that aberrant MAP kinase activity blocks differentiation in rhabdomyosarcoma and highlight trametinib as a potential therapeutic for RAS-mutated rhabdomyosarcoma.

ORGANISM(S): Homo sapiens

PROVIDER: GSE85170 | GEO | 2018/04/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-04-01 | GSE85169 | GEO
| PRJNA336377 | ENA
2019-12-25 | GSE137168 | GEO
2010-10-16 | E-GEOD-24715 | biostudies-arrayexpress
2019-12-25 | GSE136799 | GEO
2011-02-17 | E-GEOD-22520 | biostudies-arrayexpress
2013-12-31 | GSE28511 | GEO
2018-06-13 | GSE115698 | GEO
2018-03-06 | GSE108022 | GEO
2004-03-13 | GSE967 | GEO